Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963544 | 0.90 | L3MBTL1 (0.46) | POLBGAAALDH1A1RAB9ABLM | |
| SCHEMBL963546 | 0.90 | L3MBTL1 (0.46) | POLBGAAALDH1A1RAB9ABLM | |
| SCHEMBL962300 | 0.85 | LMNA (0.38) | ALDH1A1RAB9AL3MBTL1LMNAMAPK1 | |
| SCHEMBL961710 | 0.83 | L3MBTL1 (0.50) | POLBGAAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL962642 | 0.82 | L3MBTL1 (0.46) | POLBGAAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL962643 | 0.82 | L3MBTL1 (0.46) | POLBGAAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL964548 | 0.81 | PPARG (0.40) | POLBGAAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL964545 | 0.81 | PPARG (0.40) | POLBGAAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL27772577 | 0.78 | L3MBTL1 (0.43) | POLBGAAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL966214 | 0.76 | LMNA (0.36) | RAB9ALMNASMN1; SMN2PDE5ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | POLB 1580/4885GAA 1120/4885ALDH1A1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.